Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Cancer Tissue Diagnostics Market Outlook (2023 to 2033)

The global cancer tissue diagnostics market is expected to reach a market valuation of US$ 7,041 million by 2023, accelerating with a moderate CAGR of 6.5% from 2023 to 2033. The cancer tissue diagnostics market is anticipated to be valued at US$ 13,219 million by 2033 end.

The biological context of cancer cells may be captured by tissue diagnostics, making them one of the most reliable methods for making a cancer diagnosis and treatment plan. High demand and promising future growth in the cancer tissue diagnostics market might be attributed to the rising cancer rate.

Increased adoption of automated cancer diagnosis methods and technologies by research institutes facilitates quicker tumor diagnosis. The West Clinic Cancer Center, for instance, teamed with F. Hoffmann-La Roche Ltd. in September 2019 to use the BenchMark ULTRA Automated Advanced Staining System, developed by Roche, to enhance patient cancer treatment. In situ, hybridization and immunohistochemistry testing can be performed using this technology for quicker cancer tissue diagnostics.

Several factors, including the rising incidence of cancers of all kinds, the growing interest in preventative health care, the expansion of digital pathology's applications, the intensification of cancer awareness campaigns, the development of more effective diagnostic and monitoring tools, and the general improvement in diagnostic accuracy, bode well for the global cancer tissue diagnostics industry.

While the global cancer tissue diagnostics industry is expected to expand during the forecast period, its expansion is expected to be hindered by factors such as the high price of diagnostic procedures and a lack of experienced and professional workers.

Attributes Value
Cancer Tissue Diagnostics Market Size (2023) US$ 7,041 million
Cancer Tissue Diagnostics Market Projected Size (2033) US$ 13,219 million
Cancer Tissue Diagnostics Market Value CAGR (2023 to 2033) 6.5%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Factors Shaping the Future of the Cancer Tissue Diagnostics Market

Cancer Diagnostics Research to Drive the Market Demand

The rise in cancer incidence has boosted cancer tissue diagnostics research and development. According to the WHO, the global cancer burden grew in 2020, with 18 million new cases and 9.6 million deaths (WHO). Increased academic-commercial partnerships to further cancer research are likely to increase the global cancer tissue diagnostics industry.

The University of Sheffield in the United Kingdom signed a collaboration agreement with Zilico Ltd in June 2020 to develop a painless, fast, and non-invasive oral cancer diagnosis using EIS technology.

Swiss life-sciences firm Lunaphore Technologies SA develops next-generation cancer research equipment. In the same month, Epredia, a global leader in cancer and tissue diagnostics, signed a strategic distribution deal with the firm. Fast Fluidic Exchange microfluidic technology is forecast to be integrated into tissue diagnostic instruments by industry leader Lunaphore to deliver chemicals to tissue samples for quick IHC and immunofluorescence assays (IF).

Scarcity of Qualified Workers

Histology laboratories are vital to the accuracy, safety, and speed of sickness diagnosis. Histology is needed to understand illness causes and how therapies operate. Cancer rates increase the requirement for clinical histology services. 80% of cancer diagnostics involve histology. These facilities are understaffed.

According to Inside Lab 2020, only 3% of United Kingdom diagnostic labs had enough staff to perform diagnostic and regular tasks, including reporting. Germany has the lowest proportion of pathologists to practicing physicians in Europe, the United States, and Canada. Germany's ratio is 1:200, while the United States and Canada have 1:70. PubMed 2020 As many histologists retire, few are entering the field. Histology labs are struggling to process more samples with fewer workers. This could limit the cancer tissue diagnostics industry's growth.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

AI Innovations Changing Cancer Diagnosis and Treatment

Cancer remains one of the world's deadliest diseases despite significant progress in cancer treatment and detection over the previous several decades. The finest weapons doctors have against this disease are identification and treatment administered early on. However, difficulties, such as high false-positive rates and difficulty forecasting cancer treatment success, can impede the process.

Now, healthcare experts and medical researchers are discovering methods to use the latest advancements from outside of medicine - like artificial intelligence - to diagnose and treat cancer. Here are just three examples of such cutting-edge equipment.

Estimating the Likelihood of Successful Immunotherapy

Immunotherapy is a novel approach to cancer treatment that makes use of medications to stimulate the immune system to combat cancer cells better. Compared to conventional therapies like chemotherapy and radiation, this often has fewer negative side effects and better success rates. Yet not every patient has the same experience, and the efficacy of immunotherapy cannot be predicted.

This could potentially alter with the introduction of a new artificial intelligence technology. Patients likely to benefit from immunotherapy could be selected using an algorithm with routine CT scans. This may expedite their cancer treatment while also allowing doctors to treat other patients who are waiting for alternatives like chemotherapy.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Mass Spectrometry Imaging: Routine 3D Tissue Analysis is Becoming a Reality

The use of mass spectrometry for imaging purposes is a significant technological advance in spectral research. A 3D chemical map can be created by examining the spectra of individual molecules in tissue. This method has many potential applications, including the detection of hypoxic tumor sites, the characterization of spheroids, and the evaluation of alterations in the tumor microenvironment (TME). Recent technological advancements have made it possible to take these measurements at high throughput, casting doubt on the feasibility of routine 3D tumor investigations.

Optimizing Results from Next-generation Sequencing through Careful Tissue Handling

Improvements in dependability and data management are largely responsible for the growth of next-generation sequencing in the therapeutic setting. The past decade has seen NGS facilitate the discovery of novel genomic variants and driving mutations, clarifying new targets for medication development. Thanks to NGS, researchers have also been able to pinpoint more accurate predictive and prognostic biomarkers for therapy.

Genomics England launched the 100,000 Genomes Initiative in 2012, making it a leading sequencing research project in the world to promote improved diagnosis and cancer treatment decisions. The research is also expected to improve 'genome-friendly' tissue processing techniques.

Comparative View of Adjacent Cancer Tissue Diagnostics Market

Cancer Tissue Diagnostics Market:

Attributes Cancer Tissue Diagnostics Market
CAGR (2023 to 2033) 6.5%
Market Value (2023) US$ 7,041 million
Growth Factor An increase in cases of cancer is expected to drive the cancer tissue diagnostics industry.
Future Opportunities The increased emphasis on individualized medical cancer treatment is opening new horizons in the cancer tissue diagnostics industry.
Market Trends The lack of available and skilled workers is expected to retrain the growth of the cancer tissue diagnostics industry.

Molecular Diagnostics Market:

Attributes Molecular Diagnostics Market
CAGR (2023 to 2033) 5.4%
Market Value (2023) US$ 24.45 billion
Growth Factor Both increasing technological capabilities in molecular diagnostics and rising awareness of the importance of early disease diagnosis in developing countries are propelling the market forward.
Future Opportunities Market leaders in molecular diagnostics can anticipate expanding prospects in developing economies, including India, China, South Korea, Brazil, Turkey, Russia, and South Africa.
Market Trends A crucial barrier limiting the expansion of the molecular diagnostics business is inadequate reimbursements.

In-vitro Diagnostics Market:

Attributes In-vitro Diagnostics Market
CAGR (2023 to 2033) 2.9%
Market Value (2023) US$ 101.05 billion
Growth Factor The need is anticipated to be driven by the transition from centralized to point-of-care testing.
Future Opportunities Growth possibilities for market players are anticipated to emerge from developing disease-specific markers and diagnostics in the future years.
Market Trends The in vitro diagnostics market is likely to slow down in the coming years due to the adverse reimbursement scenario.

The rising cancer cell rate has resulted in a surge in interest in oncology diagnostics. This has prompted government agencies, healthcare providers, and institutions to create facilities for effective illness diagnosis and treatment. Because of this, the cancer tissue diagnostics industry is growing rapidly. Roche's uPath HER2 (4B5) and uPath HER2 Dual ISH digital pathology image analyzers are algorithms for the precise patient diagnosis of breast cancer, and they were released in 2021. This is positively changing the cancer tissue diagnostics market outlook.

Country-wise Analysis of the Cancer Tissue Diagnostics Industry

Attributes Details
The United States Value Share % (2022) 32.6%
Germany Value Share % (2022) 4.5%
Japan Value Share % (2022) 5.2%
Australia’s Growth Rate (2023 to 2033) 10.3%
China’s Growth Rate (2023 to 2033) 7.5%
India’s Growth Rate (2023 to 2033) 6.4%
The United Kingdom’s Growth Rate (2023 to 2033) 4.9%
Attributes Details
United States
  • The United States has dominated the North American cancer tissue diagnostics market. Stakeholders in the United States business are expanding in response to an uptick in cancer diagnoses and improved diagnostic tools.
  • As per the cancer tissue diagnostics market report, the average probability of a woman in the United States acquiring breast cancer in her lifetime is about 13%. An estimated 234,030 new instances of lung cancer were discovered in 2018, and there are already 541,000 Americans who have been diagnosed with lung cancer at some time.
  • These findings show the vast potential for development and expansion in the United States A cancer tissue diagnostics industry.
Japan
  • Since the last decade, cancer tissue diagnostics in Japan has become an attractive market. The sophisticated diagnostics sector and the rising need to detect lung, breast, prostate, and elsewhere malignancies are driving this cancer tissue diagnostics industry expansion in Japan.
  • According to the Global Cancer Data by Country report by the World Cancer Research Fund, the most frequent malignancies in Japan are breast cancer, lung cancer, stomach cancer, colorectum cancer, and prostate cancer, with an age-standardized rate of 248.0 cases per 100,000 people. Due to the rising need for cancer tissue diagnostic solutions, businesses in the cancer tissue diagnostics market should expect increased profits.
China
  • Supply companies in the cancer tissue diagnostics industry are taking notice of China because of its advanced medical and diagnostic sectors. The rise in cancer cases in China is helping to fuel the cancer tissue diagnostics market expansion.
  • About 4,285,033 new instances of cancer were identified in China in 2020, including 2,366,010 male and 1,919,023 female cases. According to the data presented, the crude and age-standardized death rates for men were 201.3 and 130.1 per 100,000, respectively. These projections indicate that China is likely to continue to be a focal point for the cancer tissue diagnostics industry.
Germany
  • The cancer tissue diagnostics industry in Western Europe is currently led by Germany and is expected to be led by Germany for the foreseeable future. Germany's highly established manufacturing hubs and rising awareness of the need for early cancer detection tests are driving the expansion.
  • The World Cancer Research Fund reports that the age-adjusted rate of cancer in Germany is 313.1 cases per 100,000 people. This number includes cases of lung, breast, and prostate cancers. These numbers highlight expanding markets for German makers of diagnostic tools for cancer tissue.

Competitive Landscape for the Cancer Tissue Diagnostics Industry

Top companies in the cancer tissue diagnostics industry are paying more attention to the growing demand for their products in digital pathology. This is expected to prompt strategic partnerships in the global cancer tissue diagnostics industry between technology providers and digital pathology platforms soon.

In July 2020, for instance, Koninklijke Philips N.V., a Dutch multinational conglomerate corporation and one of the world's leading electronics companies with a focus on health technology, announced that it had partnered with Proscia Inc., a Philadelphia-based provider of digital pathology platform, to establish an open ecosystem for diagnostic laboratories to boost and scale their operations on the platform of digital pathologies.

Through this partnership, Philips' iSyntax image format is expected to be integrated with the Philips Pathology SDK software toolset, and Proscia's suite of AI modules can be made available on the company's Concentric digital pathology platform.

The Swiss pharmaceutical and diagnostics conglomerate F. Hoffmann-La Roche AG announced the CE-IVD launch of its cutting-edge, fully automated digital pathology platform uPath PD-L1 (SP263) for non-small cell lung cancer research in June 2020. (NSCLC).

The firm stated that the decision was motivated by a desire to increase reliability and uniformity in diagnostic laboratories by implementing AI-powered image analysis capabilities.

Global Cancer Tissue Diagnostics Market Key Players

  • Abbott Laboratories
  • F.Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Ventana Medical Systems, Inc.
  • Bio Rad Laboratories Inc.
  • Enzo Life Sciences, Inc.
  • Abcam plc.
  • BioGenex
  • Cell Signalling Technology, Inc.
  • Agilent Technologies, Inc.
  • PerkinElmer Inc.
  • Bio SB
  • Cancer Genetics Inc.
  • Danaher Corporation
  • ROSETTA GENOMICS
  • Nanoprobes, Inc.
  • Creative-Biolabs
  • Enzo Life Sciences, Inc.
  • Sigma-Aldrich Co., LLC

Cancer Tissue Diagnostics Market by Segmentation

By Test Type:

  • Immunohistochemical (IHC) Test
    • Breast Cancer
    • Stomach (Gastric) Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Others
  • In Situ Hybridization (ISH) Test
    • Breast Cancer
    • Non-Small Cell Lung Cancer (NSCLC)
    • Bladder Cancer
    • Others

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa (MEA)

Frequently Asked Questions

What is the Present Assessed Value of the Cancer Tissue Diagnostics Market?

The market is valued at US$ 7,041 million in 2023.

What is the Cancer Tissue Diagnostics Market Size Projected by 2033?

The global cancer tissue diagnostics market size is anticipated to surpass US$ 13,219 million by 2033.

What is the CAGR Prediction for the Cancer Tissue Diagnostics Market?

The cancer tissue diagnostics market is projected to accelerate at a CAGR of 6.5% between 2023 and 2033.

Which Country Holds High Lucrativeness for Cancer Tissue Diagnostics?

The United States holds substantial prospects for cancer tissue diagnostics with a 32.6% share.

Who are the Key Cancer Tissue Diagnostics Market Players?

Key cancer tissue diagnostics market players are Abbott Laboratories, Thermo Fisher Scientific Inc., and Ventana Medical Systems.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033

        5.3.1. Immunohistochemical (IHC) Test

            5.3.1.1. Breast Cancer

            5.3.1.2. Stomach (Gastric) Cancer

            5.3.1.3. Colorectal Cancer

            5.3.1.4. Prostate Cancer

            5.3.1.5. Others

        5.3.2. In Situ Hybridization (ISH) Test

            5.3.2.1. Breast cancer

            5.3.2.2. Non-Small Cell Lung Cancer (NSCLC)

            5.3.2.3. Bladder Cance

            5.3.2.4. Others

    5.4. Y-o-Y Growth Trend Analysis By Test Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Test Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    6.1. Introduction

    6.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    6.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        6.3.1. North America

        6.3.2. Latin America

        6.3.3. Western Europe

        6.3.4. Eastern Europe

        6.3.5. South Asia and Pacific

        6.3.6. East Asia

        6.3.7. Middle East and Africa

    6.4. Market Attractiveness Analysis By Region

7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    7.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    7.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        7.2.1. By Country

            7.2.1.1. USA

            7.2.1.2. Canada

        7.2.2. By Test Type

    7.3. Market Attractiveness Analysis

        7.3.1. By Country

        7.3.2. By Test Type

    7.4. Key Takeaways

8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. Brazil

            8.2.1.2. Mexico

            8.2.1.3. Rest of Latin America

        8.2.2. By Test Type

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Test Type

    8.4. Key Takeaways

9. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Germany

            9.2.1.2. UK

            9.2.1.3. France

            9.2.1.4. Spain

            9.2.1.5. Italy

            9.2.1.6. Rest of Western Europe

        9.2.2. By Test Type

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Test Type

    9.4. Key Takeaways

10. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Poland

            10.2.1.2. Russia

            10.2.1.3. Czech Republic

            10.2.1.4. Romania

            10.2.1.5. Rest of Eastern Europe

        10.2.2. By Test Type

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Test Type

    10.4. Key Takeaways

11. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Bangladesh

            11.2.1.3. Australia

            11.2.1.4. New Zealand

            11.2.1.5. Rest of South Asia and Pacific

        11.2.2. By Test Type

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Test Type

    11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Test Type

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Test Type

    12.4. Key Takeaways

13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Test Type

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Test Type

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Test Type

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Test Type

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Test Type

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Test Type

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Test Type

    14.6. UK

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Test Type

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Test Type

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Test Type

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Test Type

    14.10. Poland

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Test Type

    14.11. Russia

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Test Type

    14.12. Czech Republic

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Test Type

    14.13. Romania

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Test Type

    14.14. India

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Test Type

    14.15. Bangladesh

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Test Type

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Test Type

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Test Type

    14.18. China

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Test Type

    14.19. Japan

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Test Type

    14.20. South Korea

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Test Type

    14.21. GCC Countries

        14.21.1. Pricing Analysis

        14.21.2. Market Share Analysis, 2022

            14.21.2.1. By Test Type

    14.22. South Africa

        14.22.1. Pricing Analysis

        14.22.2. Market Share Analysis, 2022

            14.22.2.1. By Test Type

    14.23. Israel

        14.23.1. Pricing Analysis

        14.23.2. Market Share Analysis, 2022

            14.23.2.1. By Test Type

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Test Type

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Abbott Laboratories

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. F.Hoffmann-La Roche Ltd.

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Thermo Fisher Scientific Inc.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Ventana Medical Systems, Inc.

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Bio Rad Laboratories Inc.

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Enzo Life Sciences, Inc.

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Abcam plc

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. BioGenex

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Cell Signalling Technology, Inc.

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Agilent Technologies, Inc.

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Test Type, 2018 to 2033

Table 3: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Test Type, 2018 to 2033

Table 5: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: Latin America Market Value (US$ Million) Forecast by Test Type, 2018 to 2033

Table 7: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Western Europe Market Value (US$ Million) Forecast by Test Type, 2018 to 2033

Table 9: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Eastern Europe Market Value (US$ Million) Forecast by Test Type, 2018 to 2033

Table 11: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 12: South Asia and Pacific Market Value (US$ Million) Forecast by Test Type, 2018 to 2033

Table 13: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: East Asia Market Value (US$ Million) Forecast by Test Type, 2018 to 2033

Table 15: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 16: Middle East and Africa Market Value (US$ Million) Forecast by Test Type, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Test Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 3: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 4: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 5: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 6: Global Market Value (US$ Million) Analysis by Test Type, 2018 to 2033

Figure 7: Global Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033

Figure 8: Global Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033

Figure 9: Global Market Attractiveness by Test Type, 2023 to 2033

Figure 10: Global Market Attractiveness by Region, 2023 to 2033

Figure 11: North America Market Value (US$ Million) by Test Type, 2023 to 2033

Figure 12: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 13: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 14: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 15: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 16: North America Market Value (US$ Million) Analysis by Test Type, 2018 to 2033

Figure 17: North America Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033

Figure 18: North America Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033

Figure 19: North America Market Attractiveness by Test Type, 2023 to 2033

Figure 20: North America Market Attractiveness by Country, 2023 to 2033

Figure 21: Latin America Market Value (US$ Million) by Test Type, 2023 to 2033

Figure 22: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 23: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 24: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 25: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 26: Latin America Market Value (US$ Million) Analysis by Test Type, 2018 to 2033

Figure 27: Latin America Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033

Figure 28: Latin America Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033

Figure 29: Latin America Market Attractiveness by Test Type, 2023 to 2033

Figure 30: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 31: Western Europe Market Value (US$ Million) by Test Type, 2023 to 2033

Figure 32: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 33: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 34: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 35: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 36: Western Europe Market Value (US$ Million) Analysis by Test Type, 2018 to 2033

Figure 37: Western Europe Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033

Figure 38: Western Europe Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033

Figure 39: Western Europe Market Attractiveness by Test Type, 2023 to 2033

Figure 40: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 41: Eastern Europe Market Value (US$ Million) by Test Type, 2023 to 2033

Figure 42: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 43: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 44: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 45: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 46: Eastern Europe Market Value (US$ Million) Analysis by Test Type, 2018 to 2033

Figure 47: Eastern Europe Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033

Figure 48: Eastern Europe Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033

Figure 49: Eastern Europe Market Attractiveness by Test Type, 2023 to 2033

Figure 50: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 51: South Asia and Pacific Market Value (US$ Million) by Test Type, 2023 to 2033

Figure 52: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 53: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 54: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 55: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 56: South Asia and Pacific Market Value (US$ Million) Analysis by Test Type, 2018 to 2033

Figure 57: South Asia and Pacific Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033

Figure 58: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033

Figure 59: South Asia and Pacific Market Attractiveness by Test Type, 2023 to 2033

Figure 60: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033

Figure 61: East Asia Market Value (US$ Million) by Test Type, 2023 to 2033

Figure 62: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 63: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 64: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 65: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 66: East Asia Market Value (US$ Million) Analysis by Test Type, 2018 to 2033

Figure 67: East Asia Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033

Figure 68: East Asia Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033

Figure 69: East Asia Market Attractiveness by Test Type, 2023 to 2033

Figure 70: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 71: Middle East and Africa Market Value (US$ Million) by Test Type, 2023 to 2033

Figure 72: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 73: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 74: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 75: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 76: Middle East and Africa Market Value (US$ Million) Analysis by Test Type, 2018 to 2033

Figure 77: Middle East and Africa Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033

Figure 78: Middle East and Africa Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033

Figure 79: Middle East and Africa Market Attractiveness by Test Type, 2023 to 2033

Figure 80: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Cancer Diagnostics Market

Published : August 2023

Healthcare

Molecular Diagnostics Market

Published : October 2022

Explore Healthcare Insights

View Reports

Cancer Tissue Diagnostics Market